GW Pharmaceuticals PLC- (NASDAQ:GWPH) – Equities researchers at Cantor Fitzgerald cut their FY2018 earnings estimates for GW Pharmaceuticals PLC- in a report issued on Monday, August 13th. Cantor Fitzgerald analyst E. Piros now forecasts that the biopharmaceutical company will earn ($8.26) per share for the year, down from their previous estimate of ($7.32). Cantor Fitzgerald currently has a “Overweight” rating and a $211.00 target price on the stock. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals PLC-‘s FY2019 earnings at ($2.28) EPS.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.14. The firm had revenue of $3.46 million for the quarter, compared to analyst estimates of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%.
NASDAQ:GWPH opened at $133.93 on Thursday. The firm has a market cap of $3.75 billion, a P/E ratio of -19.27 and a beta of 2.55. GW Pharmaceuticals PLC- has a 1-year low of $96.42 and a 1-year high of $164.76. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01.
A number of hedge funds have recently modified their holdings of the business. Verition Fund Management LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $322,000. Sio Capital Management LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $1,499,000. Flagship Harbor Advisors LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $109,000. Morgan Stanley increased its position in GW Pharmaceuticals PLC- by 9.8% in the 2nd quarter. Morgan Stanley now owns 378,776 shares of the biopharmaceutical company’s stock worth $52,855,000 after purchasing an additional 33,784 shares during the last quarter. Finally, Baker BROS. Advisors LP increased its position in GW Pharmaceuticals PLC- by 45.1% in the 2nd quarter. Baker BROS. Advisors LP now owns 321,800 shares of the biopharmaceutical company’s stock worth $44,904,000 after purchasing an additional 100,000 shares during the last quarter. 73.80% of the stock is currently owned by institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Recommended Story: Diversification in Investing
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.